<?xml version="1.0" encoding="UTF-8"?>
<p id="p0515">More recently, molecules with a quinoline group have been widely investigated as treatment for the new coronavirus (SARS-CoV-2), such as Chloroquine (CQ) 
 <bold>(37)</bold> and Hydroxychloroquine (HCQ) 
 <bold>(38)</bold> (
 <xref rid="f0035" ref-type="fig">Fig. 7</xref> ) that belong to the quinoline class and aminoquinoline subclass. Both are quick-absorption synthetic drugs approved to treat malaria (
 <italic>Plasmodium falciparum</italic>) by several regulating agencies in the world. CQ and HCQ are water soluble; the latter is more soluble due to presence of hydroxyl group. They are currently used to treat autoimmune diseases such as lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis as they have immunomodulatory and antithrombosis properties.
 <xref rid="b1210" ref-type="bibr">242</xref>, 
 <xref rid="b1215" ref-type="bibr">243</xref>, 
 <xref rid="b1220" ref-type="bibr">244</xref> Therefore, these drugs could be useful against COVID-19 due to the elevated levels of cytokine caused by CoV infections in humans.
 <xref rid="b1225" ref-type="bibr">
  <sup>245</sup>
 </xref>
</p>
